# Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

> **NCT07419880** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Triple -Negative Breast Cancer

## Interventions

- **DRUG:** Cromolyn, TQB2102, and Panpulimab

## Key facts

- **NCT ID:** NCT07419880
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07419880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07419880, "Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07419880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*